Manuel Menendez-Gonzalez

List of Publications by Year
in descending order

118 papers	3,717 citations	172207 29 h-index	168136 53 g-index
136 all docs	136 docs citations	136 times ranked	5665 citing authors

#	Article	IF	Citations
1	Smoking is associated with age at disease onset in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 79-83.	1.1	2
2	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
3	The "Cerebrospinal Fluid Sink Therapeutic Strategy" in Alzheimer's Disease—From Theory to Design of Applied Systems. Biomedicines, 2022, 10, 1509.	1.4	7
4	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. Neurobiology of Aging, 2021, 99, 99.e15-99.e22.	1.5	8
5	The Prion-like Properties of Amyloid-beta Peptide and Tau: Is there Any Risk of Transmitting Alzheimer's Disease During Neurosurgical Interventions?. Current Alzheimer Research, 2021, 17, 781-789.	0.7	0
6	Impact of Depression and Anxiety on Dimensions of Health-Related Quality of Life in Subjects with Parkinson's Disease Enrolled in an Association of Patients. Brain Sciences, 2021, 11, 771.	1.1	1
7	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
8	A series of cases with Huntington-like phenotype and intermediate repeats in HTT. Journal of the Neurological Sciences, 2021, 425, 117452.	0.3	3
9	Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study. Journal of Personalized Medicine, 2021, 11, 1318.	1.1	7
10	Prevalence of Depression and Anxiety in Parkinson Disease and Impact on Quality of Life: A Community-Based Study in Spain. Journal of Geriatric Psychiatry and Neurology, 2020, 33, 207-213.	1.2	39
11	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	1.5	35
12	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts. Neurology, 2020, 95, e3288-e3302.	1.5	7
13	Patients with Parkinson's Disease Show Alteration in their Visuospatial Abilities and in their Egocentric and Allocentric Spatial Orientation Measured by Card Placing Tests. Journal of Parkinson's Disease, 2020, 10, 1807-1816.	1.5	7
14	Penetrance of Parkinson's Disease in *LRRK2* p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	2.2	57
15	Performance on Daily Life Activities and Executive Functioning in Parkinson Disease. Topics in Geriatric Rehabilitation, 2020, 36, 252-259.	0.2	1
16	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. Parkinsonism and Related Disorders, 2019, 66, 151-157.	1.1	71
17	Albumin Exchange in Alzheimer's Disease: Might CSF Be an Alternative Route to Plasma?. Frontiers in Neurology, 2019, 10, 1036.	1.1	15
18	High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients. Journal of Neural Transmission, 2019, 126, 1599-1608.	1.4	11

#	Article	IF	Citations
19	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population‑Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	2.2	47
20	Genome‑wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimer's and Dementia, 2019, 15, 1333-1347.	0.4	111
21	Perrault syndrome with neurological features in a compound heterozygote for two TWNK mutations: overlap of TWNK-related recessive disorders. Journal of Translational Medicine, 2019, 17, 290.	1.8	14
22	SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease. Movement Disorders, 2019, 34, 1333-1344.	2.2	21
23	Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset. Npj Parkinson's Disease, 2019, 5, 8.	2.5	95
24	<scp>COPPADIS</scp>‑2015 (<scp>CO</scp>hort of Patients with PArkinson's <scp>DI</scp>sease in) Tj ETQq0 0 0 rgBT /Overlock 1 1000 subjects included. Results from the baseline evaluation. European Journal of Neurology, 2019, 26, 1399-1407.	1.7	32
25	Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson's disease heritability. Npj Parkinson's Disease, 2019, 5, 6.	2.5	83
26	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Neurobiology of Aging, 2019, 76, 215.e9-215.e14.	1.5	21
27	Neuropsychological Test Performance in Parkinsonism Without Dopaminergic Deficiency on [123I]-FP-CIT SPECT Imaging. Journal of the International Neuropsychological Society, 2018, 24, 646-651.	1.2	5
28	LRP10 in α-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	4.9	15
29	Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson's Disease. Brain Sciences, 2018, 8, 52.	1.1	13
30	Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 100.	1.7	20
31	Frontotemporal Lobe Degeneration as Origin of Scans Without Evidence of Dopaminergic Deficit. Frontiers in Neurology, 2018, 9, 335.	1.1	6
32	Epilepsia mioclónica en el síndrome de Down y en la enfermedad de Alzheimer. Neurología, 2017, 32, 69-73.	0.3	23
33	Association between naturally occurring antiamyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 96-97.	0.9	1
34	Identification of abnormal movements with 3D accelerometer sensors for seizure recognition. Journal of Applied Logic, 2017, 24, 54-61.	1.1	10
35	[P3‑091]: EFFECTIVE ANALYSIS OF GENE EXPRESSION FOR THE DISCOVERY OF BIOMARKERS AND THERAPEUTIC TARGETS FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P968.	0.4	0
36	Transient Global Amnesia. Journal of Neurosciences in Rural Practice, 2017, 08, S102-S102.	0.3	1

#	Article	IF	Citations
37	The Role of Innate Immune System Receptors in Epilepsy Research. CNS and Neurological Disorders - Drug Targets, 2017, 16, 749-762.	0.8	8
38	Implantable Systems for Continuous Liquorpheresis and CSF Replacement. Cureus, 2017, 9, e1022.	0.2	9
39	Mechanical Dilution of Beta-amyloid Peptide and Phosphorylated Tau Protein in Alzheimer's Disease: Too Simple to be True?. Cureus, 2017, 9, e1062.	0.2	4
40	Learning Fuzzy Models with a SAX-based Partitioning for Simulated Seizure Recognition. Advances in Intelligent Systems and Computing, 2017, , 20-30.	0.5	0
41	Comparison of Extracellular and Intracellular Blood Compartments Highlights Redox Alterations in Alzheimer's and Mild Cognitive Impairment Patients. Current Alzheimer Research, 2016, 14, 112-122.	0.7	33
42	Pre-Clinical Study on the Detection of Simulated Epileptic Seizures. International Journal of Uncertainty, Fuzziness and Knowlege-Based Systems, 2016, 24, 33-46.	0.9	2
43	Unrevealing the diagnoses of a sample of cases with hard-to-classify tremor and normal DaT-SPECT. Parkinsonism and Related Disorders, 2016, 22, e129.	1.1	0
44	Generalized Models for the Classification of Abnormal Movements in Daily Life and its Applicability to Epilepsy Convulsion Recognition. International Journal of Neural Systems, 2016, 26, 1650037.	3.2	42
45	COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global "clinical evaluations, serum biomarkers, genetic studies and neuroimaging" prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. BMC Neurology, 2016, 16, 26.	0.8	66
46	Volumetry of the olfactory bulbs and tracts in the differential diagnosis of Parkinson's disease from parkinsonisms. Parkinsonism and Related Disorders, 2016, 22, e157.	1.1	0
47	Manual Planimetry of the Medial Temporal Lobe Versus Automated Volumetry of the Hippocampus in the Diagnosis of Alzheimer's Disease. Cureus, 2016, 8, e544.	0.2	10
48	Comparing ACO Approaches in Epilepsy Seizures. Lecture Notes in Computer Science, 2016, , 261-272.	1.0	1
49	Structural Neuroimaging of the Medial Temporal Lobe in Alzheimer's Disease Clinical Trials. Journal of Alzheimer's Disease, 2015, 48, 581-589.	1.2	11
50	Editorial: Neuropsychology and Neuropsychiatry of Neurodegenerative Disorders. Frontiers in Aging Neuroscience, 2015, 7, 227.	1.7	1
51	Magnetic Resonance Techniques Applied to the Diagnosis and Treatment of Parkinson's Disease. Frontiers in Neurology, 2015, 6, 146.	1.1	12
52	Fuzzy rule learning with ACO in epilepsy crisis identification. , 2015, , .		5
53	P1-153: The 2D-MTA is a feasible method for assessing atrophy of the medial temporal lobe in daily clinical practice. , 2015, 11, P403-P403.		0
54	Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Annals of Neurology, 2015, 77, 447-457.	2.8	48

#	Article	IF	Citations
55	Enhancing medical journalism from Internet Medical Society. International Journal of Case Reports and Images, 2015, 6, 537.	0.0	0
56	Indices of Regional Brain Atrophy: Formulae and Nomenclature. Cureus, 2015, 7, e295.	0.2	3
57	MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available neuroimaging. Frontiers in Aging Neuroscience, 2014, 6, 23.	1.7	16
58	The many questions on the use of biomarkers for neurodegenerative diseases in clinical practice. Frontiers in Aging Neuroscience, 2014, 6, 45.	1.7	6
59	Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study. Frontiers in Aging Neuroscience, 2014, 6, 56.	1.7	31
60	Routine lumbar puncture for the early diagnosis of Alzheimer's disease. Is it safe?. Frontiers in Aging Neuroscience, 2014, 6, 65.	1.7	21
61	The yearly rate of Relative Thalamic Atrophy (yrRTA): a simple 2D/3D method for estimating deep gray matter atrophy in Multiple Sclerosis. Frontiers in Aging Neuroscience, 2014, 6, 219.	1.7	6
62	Biomarkers in neurodegenerative disorders: translating research into clinical practice. Frontiers in Aging Neuroscience, 2014, 6, 281.	1.7	4
63	Feasibility of the Medial Temporal lobe Atrophy index (MTAi) and derived methods for measuring atrophy of the medial temporal lobe. Frontiers in Aging Neuroscience, 2014, 6, 305.	1.7	8
64	The screening of the 3′UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson's disease. Journal of Human Genetics, 2014, 59, 346-348.	1.1	14
65	MiRNA Profile in the Substantia Nigra of Parkinson's Disease and Healthy Subjects. Journal of Molecular Neuroscience, 2014, 54, 830-836.	1.1	58
66	Atlas of Biomarkers for Alzheimer's Disease. , 2014, , .		5
67	Orquestic regulation of neurotransmitters on reward-seeking behavior. International Archive of Medicine, 2014, 7, 29.	1.2	20
68	Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. Neuroscience Letters, 2014, 562, 45-49.	1.0	30
69	Implications of movement-related cortical potential for understanding neural adaptations in muscle strength tasks. International Archive of Medicine, 2014, 7, 9.	1.2	8
70	Early Diagnosis and Risk of Conversion from Presymptomatic Stages. , 2014, , 1-15.		1
71	Application of Alzheimer Biomarkers in Clinical Practice. , 2014, , 27-36.		0
72	Tracking the Progression. , 2014, , 23-26.		0

#	Article	IF	Citations
73	Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. Journal of Neurology, 2013, 260, 1420-1422.	1.8	132
74	Mutational Screening of PARKIN Identified a 3′ UTR Variant (rs62637702) Associated with Parkinson's Disease. Journal of Molecular Neuroscience, 2013, 50, 264-269.	1.1	11
75	The mirror neuron system in post-stroke rehabilitation. International Archive of Medicine, 2013, 6, 41.	1.2	56
76	<i>SPG7</i> mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V. Clinical Genetics, 2013, 83, 257-262.	1.0	94
77	Isolation and characterization of entomopathogenic bacteria from soil samples from the western region of Cuba. Journal of Vector Ecology, 2013, 38, 46-52.	0.5	6
78	Time perception impairs sensory-motor integration in Parkinson's disease. International Archive of Medicine, 2013, 6, 39.	1.2	19
79	Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction. CNS and Neurological Disorders - Drug Targets, 2013, 12, 641-664.	0.8	15
80	Panic attack triggering myocardial ischemia documented by myocardial perfusion imaging study. A case report. International Archive of Medicine, 2012, 5, 24.	1.2	5
81	Functional coupling of sensorimotor and associative areas during a catching ball task: a qEEG coherence study. International Archive of Medicine, 2012, 5, 9.	1.2	9
82	A Search for SNCA 3′ UTR Variants Identified SNP rs356165 as a Determinant of Disease Risk and Onset Age in Parkinson's Disease. Journal of Molecular Neuroscience, 2012, 47, 425-430.	1.1	49
83	Clinical Implication of Meissner's Corpuscles. CNS and Neurological Disorders - Drug Targets, 2012, 11, 856-868.	0.8	18
84	Evidence of Nestin-Positive Cells in the Human Cutaneus Meissner and Pacinian Corpuscles. CNS and Neurological Disorders - Drug Targets, 2012, 11, 869-877.	0.8	9
85	Immunotherapy for Alzheimer's Disease: Rational Basis in Ongoing Clinical Trials. Current Pharmaceutical Design, 2011, 17, 508-520.	0.9	50
86	Vasomotor Reactivity Is Similarly Impaired in Patients with Alzheimer's Disease and Patients with Amyloid Hemorrhage. , 2011, 21, e83-e85.		17
87	Effects of Methylphenidate on performance of a practical pistol shooting task: a quantitative electroencephalography (qEEG) study. International Archive of Medicine, 2011, 4, 6.	1.2	4
88	Lack of association between protocadherin 11-X/Y (PCDH11X and PCDH11Y) polymorphisms and late onset Alzheimer's disease. Brain Research, 2011, 1383, 252-256.	1.1	16
89	Late-onset Alzheimer's disease is associated with mitochondrial DNA 7028C/haplogroup H and D310 poly-C tract heteroplasmy. Neurogenetics, 2011, 12, 345-346.	0.7	33
90	Amyloid Precursor Protein Gene (APP) Variation in Late-Onset Alzheimer's Disease. Journal of Molecular Neuroscience, 2011, 45, 5-9.	1.1	4

#	Article	IF	Citations
91	Analysis of the *Micro‐RNA‐133* and *PITX3* genes in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1234-1239.	1.1	33
92	Cognitive impairment in Parkinson's disease without dementia. Movement Disorders, 2010, 25, 2136-2141.	2.2	36
93	Partial motor status epilepticus as a clinical manifestation of carotid stenosis. International Archive of Medicine, 2010, 3, 18.	1.2	2
94	Dopaminergic reward system: a short integrative review. International Archive of Medicine, 2010, 3, 24.	1.2	293
95	Single neuron electroporation in manipulating and measuring the central nervous system. International Archive of Medicine, 2010, 3, 28.	1.2	2
96	FGF20 rs12720208 SNP and microRNA-433 variation: No association with Parkinson's disease in Spanish patients. Neuroscience Letters, 2010, 479, 22-25.	1.0	46
97	Semantic Markers in the Diagnosis of Neurodegenerative Dementias. Dementia and Geriatric Cognitive Disorders, 2009, 28, 267-274.	0.7	29
98	Action naming is impaired in Parkinson disease patients. Neuropsychologia, 2009, 47, 3271-3274.	0.7	83
99	Defining the profile of International Archives of Medicine. International Archive of Medicine, 2008, 1, 1.	1.2	10
100	Plasmatic level of neurosin predicts outcome of mild cognitive impairment. International Archive of Medicine, 2008, 1, 11.	1.2	6
101	Partial trisomy 13q22-qter associated to leukoencephalopathy and late onset generalised epilepsy. International Archive of Medicine, 2008, 1, 5.	1.2	11
102	Value of Measuring Plasmatic Levels of Neurosin in the Diagnosis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 59-67.	1.2	19
103	The Sp1/Egr1-tandem Repeat Polymorphism in the 5-Lipoxygenase Gene Promoter is not Associated With Late Onset Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2008, 22, 177-180.	0.6	10
104	Cerebral Gas Embolism Caused by Pleural Fibrinolytic Treatment. Stroke, 2007, 38, 2602-2604.	1.0	18
105	Myocyte enhancing factor-2A in Alzheimer's disease: Genetic analysis and association with MEF2A-polymorphisms. Neuroscience Letters, 2007, 411, 47-51.	1.0	16
106	A new de novo Notch3 mutation causing CADASIL. European Journal of Neurology, 2006, 13, 628-631.	1.7	45
107	Sodium chloride regulates Extracellular Regulated Kinase 1/2 in different tumor cell lines. Molecular and Cellular Biochemistry, 2006, 293, 93-101.	1.4	5
108	Hypertonicity activates GSK3β in tumor cells. Molecular and Cellular Biochemistry, 2006, 291, 93-100.	1.4	3

#	Article	IF	Citations
109	Transient Global Amnesia. Archives of Neurology, 2006, 63, 1334.	4.9	28
110	Deletion of DNA sequences of using a polymerase chain reaction based approach. Electronic Journal of Biotechnology, 2006, 9, 0-0.	1.2	4
111	Down syndrome, Alzheimer's disease and seizures. Brain and Development, 2005, 27, 246-252.	0.6	157
112	Exacerbation of Lewy bodies dementia due to memantine. Journal of Alzheimer's Disease, 2005, 8, 289-291.	1.2	40
113	APP Processing and the APP-KPI Domain Involvement in the Amyloid Cascade. Neurodegenerative Diseases, 2005, 2, 277-283.	0.8	43
114	Pathological and clinical heterogeneity of presenilin 1 gene mutations. Journal of Alzheimer's Disease, 2004, 6, 475-482.	1.2	28
115	Relation between type of personality and academic performance among Malaysian health sciences students. International Archive of Medicine, 0, , .	1.2	4
116	Planimetry of the medial temporal lobe: a feasible method for supporting the diagnosis of Alzheimer's disease in clinical practice. Neurology and Neuroscience, 0, , .	0.0	1
117	Postural control modulation during motor imagery tasks: a systematic review. International Archive of Medicine, 0, , .	1.2	2
118	Biomarcadores para el diagnóstico de la Enfermedad de Alzheimer. Biomedicina, 0, , .	0.0	0